Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
about
Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer[Preliminary Study of Differentially Expressed Serum Peptides of Advanced NSCLC Patients Responsive to EGFR-TKI and Their Clinical Significance].Metaboloptics: Visualization of the tumor functional landscape via metabolic and vascular imaging.
P2860
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
@ast
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
@en
type
label
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
@ast
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
@en
prefLabel
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
@ast
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
@en
P2093
P2860
P356
P1476
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
@en
P2093
Hongyun Zhao
Jianwei Zhang
Jing Zhang
Jingxun Wu
Wenfeng Fang
Wenhua Liang
P2860
P304
P356
10.2147/OTT.S51887
P407
P577
2013-10-21T00:00:00Z